<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03577171</url>
  </required_header>
  <id_info>
    <org_study_id>ABI-H0731-202</org_study_id>
    <nct_id>NCT03577171</nct_id>
  </id_info>
  <brief_title>A Study Evaluating ABI-H0731+ Entecavir vs Entecavir Alone for the Treatment of Viremic HBeAg-positive Participants With Chronic Hepatitis B Virus Infection (cHBV)</brief_title>
  <official_title>A Phase 2a, Multi-center, Double-blind, Placebo-controlled Study Evaluating ABI-H0731+ Entecavir vs Entecavir Alone for the Treatment of Viremic HBeAg-positive Patients With Chronic Hepatitis B</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assembly Biosciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assembly Biosciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if ABI-H0731 given in combination with a standard&#xD;
      of care (SOC) entecavir (ETV) is safe and effective in participants with chronic hepatitis B&#xD;
      infection (cHBV)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 2a, multi-center, double-blind, placebo-controlled study evaluating&#xD;
      ABI-H0731+ ETV vs ETV alone for the treatment of viremic hepatitis B &quot;e&quot; antigen&#xD;
      (HBeAg)-positive participants with cHBV.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 19, 2018</start_date>
  <completion_date type="Actual">June 21, 2019</completion_date>
  <primary_completion_date type="Actual">June 21, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Mean log10 HBV DNA From Baseline (Day 1) to Week 12 or Week 24 on ABI H0731 + SOC ETV as Compared to Placebo + SOC ETV</measure>
    <time_frame>Baseline, Week 12, and Week 24</time_frame>
    <description>Hepatitis B virus (HBV) DNA was measured using COBAS TaqMan Version 2.0. The lower limit of quantitation (LLOQ) was 20 IU/mL and the limit of detection (LOD) was 10 IU/mL.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants One or More Adverse Events</measure>
    <time_frame>Up to Follow-up (maximum up to Week 36)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Premature Study Discontinuation</measure>
    <time_frame>Up to Follow-up (maximum up to Week 36)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With One or More Abnormal Safety Laboratory Result</measure>
    <time_frame>Up to Week 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With a Clinically-significant Electrocardiogram Abnormality</measure>
    <time_frame>Up to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With a Clinically-significant Change in Vital Signs</measure>
    <time_frame>Baseline and up to Week 24</time_frame>
    <description>Vital signs assessed were body temperature, respiratory rate, and pulse rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Abnormal Alanine Aminotransferase (ALT) at Baseline Who Have Normal ALT at Week 24 on ABI-H0731 + SOC ETV as Compared to Placebo + SOC ETV</measure>
    <time_frame>Baseline to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With a Decline in Viral DNA to Below Limit of Quantitation on ABI-H0731 + SOC ETV as Compared to Placebo + SOC ETV</measure>
    <time_frame>Baseline, Weeks 2, 4, 8, 12, 16, 20, and 24</time_frame>
    <description>HBV DNA was measured using COBAS TaqMan Version 2.0. The LLOQ was 20 IU/mL and the LOD was 10 IU/mL. The number of participants with HBV DNA below the limit of quantitation (&lt;20 IU/mL) and target detected (≥10 IU/mL) was assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Time to Viral Suppression, Defined as HBV DNA &lt;20 IU/mL, on ABI-H0731 + ETV as Compared to Placebo + ETV</measure>
    <time_frame>Baseline, Weeks 2, 4, 8, 12, 16, 20, and 24</time_frame>
    <description>Median time to viral suppression will be calculated and evaluated between participants on ABI-H0731 + ETV as compared to placebo + ETV.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Emergence of Resistant HBV Variants on ABI-H0731 + SOC ETV as Compared to Placebo + SOC ETV</measure>
    <time_frame>Up to Week 36</time_frame>
    <description>Emergence of a resistant HBV variant was defined as an increase of ≥1 log10 IU/mL from the nadir in HBV DNA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough Levels of ABI-H0731 on ABI-H0731 + SOC ETV Therapy</measure>
    <time_frame>Before dosing at Baseline (Day 1), Weeks 2, 4, 12, and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough Levels of ETV on ABI-H0731 + ETV Therapy as Compared With Placebo + ETV Therapy</measure>
    <time_frame>Before dosing at Baseline (Day 1), Weeks 2, 4, 12, and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough to Peak Ratios of ABI-H0731 on ABI-H0731 + ETV Therapy</measure>
    <time_frame>Baseline, Weeks 2, 4, 12, and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough to Peak Ratios of ETV on ABI-H0731 + ETV Therapy as Compared With Placebo + ETV Therapy</measure>
    <time_frame>Baseline, Weeks 2, 4, 12, 24, and 28</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <arm_group>
    <arm_group_label>ABI-H0731 + SOC ETV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with cHBV who are currently not being treated will receive ABI-H0731 along with SOC ETV tablets orally for 24 weeks. Eligible participants may enter a separate extension study after Week 24 to continue open-label ABI-H0731 for up to an additional year if necessary.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + SOC ETV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with cHBV who are currently not being treated will receive matching placebo along with SOC ETV tablets orally for 24 weeks. Eligible participants may enter a separate extension study after Week 24 to start treatment on open-label ABI-H0731 for up to a year if necessary.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABI-H0731</intervention_name>
    <description>Participants will receive 300mg QD of ABI-H0731 tablets orally.</description>
    <arm_group_label>ABI-H0731 + SOC ETV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SOC ETV</intervention_name>
    <description>Participants will receive SOC ETV (0.5 mg QD) orally as per approved package insert.</description>
    <arm_group_label>ABI-H0731 + SOC ETV</arm_group_label>
    <arm_group_label>Placebo + SOC ETV</arm_group_label>
    <other_name>Entecavir</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>Participants will receive matching QD placebo tablets orally.</description>
    <arm_group_label>Placebo + SOC ETV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Male or female between ages 18 and 70 years&#xD;
&#xD;
          -  HBeAg-positive at screening&#xD;
&#xD;
          -  In good general health except for cHBV&#xD;
&#xD;
          -  HBV viral load ≥2×105 IU/mL&#xD;
&#xD;
          -  Hepatitis B surface antigen (HBsAg) &gt;1000 IU/mL at screening&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Any prior treatment with lamivudine or telbivudine, previous treatment with an&#xD;
             investigational agent for HBV other than ABI-H0731; or any other SOC treatment for &gt;4&#xD;
             weeks&#xD;
&#xD;
          -  Co-infection with HIV, hepatitis C virus (HCV), hepatitis E virus (HEV) or hepatitis D&#xD;
             virus (HDV)&#xD;
&#xD;
          -  History or evidence of hepatic decompensation (including gastrointestinal bleeding or&#xD;
             esophageal varices) at any time prior to or at time of screening&#xD;
&#xD;
          -  Clinically significant cardiac or pulmonary disease, chronic or recurrent renal or&#xD;
             urinary tract disease, liver disease other than HBV, endocrine disorder, autoimmune&#xD;
             disorder, diabetes mellitus requiring treatment with insulin or hypoglycemic agents,&#xD;
             neuromuscular, musculoskeletal, or mucocutaneous conditions requiring frequent&#xD;
             treatment, seizure disorders requiring treatment, or other medical conditions&#xD;
             requiring frequent medical management or pharmacologic or surgical treatment that in&#xD;
             the opinion of the Investigator or the Sponsor makes the participant unsuitable for&#xD;
             the study&#xD;
&#xD;
          -  Previous treatment with an investigational agent for HBV other than ABI-H0731 in the&#xD;
             last 6 months before screening&#xD;
&#xD;
          -  History of hepatocellular carcinoma (HCC)&#xD;
&#xD;
          -  Females who are lactating or pregnant or wish to become pregnant are excluded from the&#xD;
             study&#xD;
&#xD;
          -  Exclusionary laboratory parameters at screening:&#xD;
&#xD;
               -  Platelet count &lt;100,000/mm3&#xD;
&#xD;
               -  Albumin &lt;lower limit of normal (LLN)&#xD;
&#xD;
               -  Direct bilirubin &gt;1.2×upper limit of normal (ULN)&#xD;
&#xD;
               -  Alanine aminotransferase (ALT) &gt;10×ULN at screening&#xD;
&#xD;
               -  Serum alpha fetoprotein (AFP) ≥100 ng/mL. If AFP at Screening is &gt;ULN but &lt;100&#xD;
                  ng/mL, participant is eligible if a hepatic imaging study prior to the initiation&#xD;
                  of study drug reveals no lesions suspicious of possible HCC&#xD;
&#xD;
               -  International Normalized Ratio (INR) &gt;1.5×ULN&#xD;
&#xD;
               -  Glomerular filtration rate (GFR) &lt;60 mL/min/1.73 m2 by Chronic Kidney Disease&#xD;
                  Epidemiology Collaboration (CKD-EPI) equation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Southern California Research Center</name>
      <address>
        <city>Coronado</city>
        <state>California</state>
        <zip>92118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asia Pacific Liver Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research and Education</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Quest Clinical Research</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University School of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU Langone Health</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xiaoli Ma MD</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GI Research Institute</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 2K5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto Liver Center</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M6H 3M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Hong Kong, Queen Mary Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Waikato Hospital</name>
      <address>
        <city>Hamilton</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King's College London</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Hong Kong</country>
    <country>New Zealand</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>June 6, 2018</study_first_submitted>
  <study_first_submitted_qc>July 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 5, 2018</study_first_posted>
  <results_first_submitted>December 1, 2020</results_first_submitted>
  <results_first_submitted_qc>January 8, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">January 28, 2021</results_first_posted>
  <disposition_first_submitted>June 10, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>January 8, 2021</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">January 28, 2021</disposition_first_posted>
  <last_update_submitted>January 8, 2021</last_update_submitted>
  <last_update_submitted_qc>January 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cHBV</keyword>
  <keyword>HBV</keyword>
  <keyword>HBeAg-positive</keyword>
  <keyword>hepatitis B</keyword>
  <keyword>vebicorvir</keyword>
  <keyword>VBR</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Entecavir</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 18, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/71/NCT03577171/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 6, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/71/NCT03577171/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>ABI-H0731 + SOC ETV</title>
          <description>Participants with chronic hepatitis B infection (cHBV) who are currently not being treated will receive ABI-H0731 along with standard of care (SOC) entecavir (ETV) tablets orally for 24 weeks. Eligible participants may enter a separate extension study after Week 24 to continue open-label ABI-H0731 for up to an additional year if necessary.&#xD;
ABI-H0731: Participants will receive 300mg QD of ABI-H0731 tablets orally.&#xD;
SOC ETV: Participants will receive SOC ETV (0.5 mg QD) orally as per approved package insert.</description>
        </group>
        <group group_id="P2">
          <title>Placebo + SOC ETV</title>
          <description>Participants with cHBV who are currently not being treated will receive matching placebo along with SOC ETV tablets orally for 24 weeks. Eligible participants may enter a separate extension study after Week 24 to start treatment on open-label ABI-H0731 for up to a year if necessary.&#xD;
SOC ETV: Participants will receive SOC ETV (0.5 mg QD) orally as per approved package insert.&#xD;
Placebo Oral Tablet: Participants will receive matching QD placebo tablets orally.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Randomized participants</population>
      <group_list>
        <group group_id="B1">
          <title>ABI-H0731 + SOC ETV</title>
          <description>Participants with cHBV who are currently not being treated will receive ABI-H0731 along with SOC ETV tablets orally for 24 weeks. Eligible participants may enter a separate extension study after Week 24 to continue open-label ABI-H0731 for up to an additional year if necessary.&#xD;
ABI-H0731: Participants will receive 300mg QD of ABI-H0731 tablets orally.&#xD;
SOC ETV: Participants will receive SOC ETV (0.5 mg QD) orally as per approved package insert.</description>
        </group>
        <group group_id="B2">
          <title>Placebo + SOC ETV</title>
          <description>Participants with cHBV who are currently not being treated will receive matching placebo along with SOC ETV tablets orally for 24 weeks. Eligible participants may enter a separate extension study after Week 24 to start treatment on open-label ABI-H0731 for up to a year if necessary.&#xD;
SOC ETV: Participants will receive SOC ETV (0.5 mg QD) orally as per approved package insert.&#xD;
Placebo Oral Tablet: Participants will receive matching QD placebo tablets orally.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="25"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.7" spread="14.13"/>
                    <measurement group_id="B2" value="34.1" spread="11.39"/>
                    <measurement group_id="B3" value="34.9" spread="12.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>New Zealand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hong Kong</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Mean log10 HBV DNA From Baseline (Day 1) to Week 12 or Week 24 on ABI H0731 + SOC ETV as Compared to Placebo + SOC ETV</title>
        <description>Hepatitis B virus (HBV) DNA was measured using COBAS TaqMan Version 2.0. The lower limit of quantitation (LLOQ) was 20 IU/mL and the limit of detection (LOD) was 10 IU/mL.</description>
        <time_frame>Baseline, Week 12, and Week 24</time_frame>
        <population>Intent-to-treat (ITT) population: all randomized participants</population>
        <group_list>
          <group group_id="O1">
            <title>ABI-H0731 + SOC ETV</title>
            <description>Participants with cHBV who are currently not being treated will receive ABI-H0731 along with SOC ETV tablets orally for 24 weeks. Eligible participants may enter a separate extension study after Week 24 to continue open-label ABI-H0731 for up to an additional year if necessary.&#xD;
ABI-H0731: Participants will receive 300mg QD of ABI-H0731 tablets orally.&#xD;
SOC ETV: Participants will receive SOC ETV (0.5 mg QD) orally as per approved package insert.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + SOC ETV</title>
            <description>Participants with cHBV who are currently not being treated will receive matching placebo along with SOC ETV tablets orally for 24 weeks. Eligible participants may enter a separate extension study after Week 24 to start treatment on open-label ABI-H0731 for up to a year if necessary.&#xD;
SOC ETV: Participants will receive SOC ETV (0.5 mg QD) orally as per approved package insert.&#xD;
Placebo Oral Tablet: Participants will receive matching QD placebo tablets orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mean log10 HBV DNA From Baseline (Day 1) to Week 12 or Week 24 on ABI H0731 + SOC ETV as Compared to Placebo + SOC ETV</title>
          <description>Hepatitis B virus (HBV) DNA was measured using COBAS TaqMan Version 2.0. The lower limit of quantitation (LLOQ) was 20 IU/mL and the limit of detection (LOD) was 10 IU/mL.</description>
          <population>Intent-to-treat (ITT) population: all randomized participants</population>
          <units>Log10 International Units (IU)/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.91" spread="0.890"/>
                    <measurement group_id="O2" value="8.03" spread="0.999"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.45" spread="1.027"/>
                    <measurement group_id="O2" value="-3.30" spread="1.182"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.33" spread="1.594"/>
                    <measurement group_id="O2" value="-4.20" spread="0.976"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Least Squares (LS) Mean Difference ABI-H0731 + SOC ETV minus Placebo + SOC ETV at Week 12</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0077</p_value>
            <method>Repeated measures analysis</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-1.154</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.986</ci_lower_limit>
            <ci_upper_limit>-0.322</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Least Squares Mean Difference ABI-H0731 + SOC ETV minus Placebo + SOC ETV at Week 24</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0084</p_value>
            <method>Repeated measures analysis</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-1.141</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.973</ci_lower_limit>
            <ci_upper_limit>-0.309</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants One or More Adverse Events</title>
        <time_frame>Up to Follow-up (maximum up to Week 36)</time_frame>
        <population>Safety population: all randomized participants who received any amount of study drug</population>
        <group_list>
          <group group_id="O1">
            <title>ABI-H0731 + SOC ETV</title>
            <description>Participants with cHBV who are currently not being treated will receive ABI-H0731 along with SOC ETV tablets orally for 24 weeks. Eligible participants may enter a separate extension study after Week 24 to continue open-label ABI-H0731 for up to an additional year if necessary.&#xD;
ABI-H0731: Participants will receive 300mg QD of ABI-H0731 tablets orally.&#xD;
SOC ETV: Participants will receive SOC ETV (0.5 mg QD) orally as per approved package insert.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + SOC ETV</title>
            <description>Participants with cHBV who are currently not being treated will receive matching placebo along with SOC ETV tablets orally for 24 weeks. Eligible participants may enter a separate extension study after Week 24 to start treatment on open-label ABI-H0731 for up to a year if necessary.&#xD;
SOC ETV: Participants will receive SOC ETV (0.5 mg QD) orally as per approved package insert.&#xD;
Placebo Oral Tablet: Participants will receive matching QD placebo tablets orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants One or More Adverse Events</title>
          <population>Safety population: all randomized participants who received any amount of study drug</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Premature Study Discontinuation</title>
        <time_frame>Up to Follow-up (maximum up to Week 36)</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>ABI-H0731 + SOC ETV</title>
            <description>Participants with cHBV who are currently not being treated will receive ABI-H0731 along with SOC ETV tablets orally for 24 weeks. Eligible participants may enter a separate extension study after Week 24 to continue open-label ABI-H0731 for up to an additional year if necessary.&#xD;
ABI-H0731: Participants will receive 300mg QD of ABI-H0731 tablets orally.&#xD;
SOC ETV: Participants will receive SOC ETV (0.5 mg QD) orally as per approved package insert.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + SOC ETV</title>
            <description>Participants with cHBV who are currently not being treated will receive matching placebo along with SOC ETV tablets orally for 24 weeks. Eligible participants may enter a separate extension study after Week 24 to start treatment on open-label ABI-H0731 for up to a year if necessary.&#xD;
SOC ETV: Participants will receive SOC ETV (0.5 mg QD) orally as per approved package insert.&#xD;
Placebo Oral Tablet: Participants will receive matching QD placebo tablets orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Premature Study Discontinuation</title>
          <population>ITT population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With One or More Abnormal Safety Laboratory Result</title>
        <time_frame>Up to Week 36</time_frame>
        <population>Safety population: all randomized participants who received any amount of study drug</population>
        <group_list>
          <group group_id="O1">
            <title>ABI-H0731 + SOC ETV</title>
            <description>Participants with cHBV who are currently not being treated will receive ABI-H0731 along with SOC ETV tablets orally for 24 weeks. Eligible participants may enter a separate extension study after Week 24 to continue open-label ABI-H0731 for up to an additional year if necessary.&#xD;
ABI-H0731: Participants will receive 300mg QD of ABI-H0731 tablets orally.&#xD;
SOC ETV: Participants will receive SOC ETV (0.5 mg QD) orally as per approved package insert.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + SOC ETV</title>
            <description>Participants with cHBV who are currently not being treated will receive matching placebo along with SOC ETV tablets orally for 24 weeks. Eligible participants may enter a separate extension study after Week 24 to start treatment on open-label ABI-H0731 for up to a year if necessary.&#xD;
SOC ETV: Participants will receive SOC ETV (0.5 mg QD) orally as per approved package insert.&#xD;
Placebo Oral Tablet: Participants will receive matching QD placebo tablets orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With One or More Abnormal Safety Laboratory Result</title>
          <population>Safety population: all randomized participants who received any amount of study drug</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With a Clinically-significant Electrocardiogram Abnormality</title>
        <time_frame>Up to Week 24</time_frame>
        <population>Safety population: all randomized participants who received any amount of study drug</population>
        <group_list>
          <group group_id="O1">
            <title>ABI-H0731 + SOC ETV</title>
            <description>Participants with cHBV who are currently not being treated will receive ABI-H0731 along with SOC ETV tablets orally for 24 weeks. Eligible participants may enter a separate extension study after Week 24 to continue open-label ABI-H0731 for up to an additional year if necessary.&#xD;
ABI-H0731: Participants will receive 300mg QD of ABI-H0731 tablets orally.&#xD;
SOC ETV: Participants will receive SOC ETV (0.5 mg QD) orally as per approved package insert.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + SOC ETV</title>
            <description>Participants with cHBV who are currently not being treated will receive matching placebo along with SOC ETV tablets orally for 24 weeks. Eligible participants may enter a separate extension study after Week 24 to start treatment on open-label ABI-H0731 for up to a year if necessary.&#xD;
SOC ETV: Participants will receive SOC ETV (0.5 mg QD) orally as per approved package insert.&#xD;
Placebo Oral Tablet: Participants will receive matching QD placebo tablets orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Clinically-significant Electrocardiogram Abnormality</title>
          <population>Safety population: all randomized participants who received any amount of study drug</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With a Clinically-significant Change in Vital Signs</title>
        <description>Vital signs assessed were body temperature, respiratory rate, and pulse rate</description>
        <time_frame>Baseline and up to Week 24</time_frame>
        <population>Safety population: all randomized participants who received any amount of study drug</population>
        <group_list>
          <group group_id="O1">
            <title>ABI-H0731 + SOC ETV</title>
            <description>Participants with cHBV who are currently not being treated will receive ABI-H0731 along with SOC ETV tablets orally for 24 weeks. Eligible participants may enter a separate extension study after Week 24 to continue open-label ABI-H0731 for up to an additional year if necessary.&#xD;
ABI-H0731: Participants will receive 300mg QD of ABI-H0731 tablets orally.&#xD;
SOC ETV: Participants will receive SOC ETV (0.5 mg QD) orally as per approved package insert.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + SOC ETV</title>
            <description>Participants with cHBV who are currently not being treated will receive matching placebo along with SOC ETV tablets orally for 24 weeks. Eligible participants may enter a separate extension study after Week 24 to start treatment on open-label ABI-H0731 for up to a year if necessary.&#xD;
SOC ETV: Participants will receive SOC ETV (0.5 mg QD) orally as per approved package insert.&#xD;
Placebo Oral Tablet: Participants will receive matching QD placebo tablets orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Clinically-significant Change in Vital Signs</title>
          <description>Vital signs assessed were body temperature, respiratory rate, and pulse rate</description>
          <population>Safety population: all randomized participants who received any amount of study drug</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Abnormal Alanine Aminotransferase (ALT) at Baseline Who Have Normal ALT at Week 24 on ABI-H0731 + SOC ETV as Compared to Placebo + SOC ETV</title>
        <time_frame>Baseline to Week 24</time_frame>
        <population>Participants in the ITT population with abnormal ALT at Baseline</population>
        <group_list>
          <group group_id="O1">
            <title>ABI-H0731 + SOC ETV</title>
            <description>Participants with cHBV who are currently not being treated will receive ABI-H0731 along with SOC ETV tablets orally for 24 weeks. Eligible participants may enter a separate extension study after Week 24 to continue open-label ABI-H0731 for up to an additional year if necessary.&#xD;
ABI-H0731: Participants will receive 300mg QD of ABI-H0731 tablets orally.&#xD;
SOC ETV: Participants will receive SOC ETV (0.5 mg QD) orally as per approved package insert.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + SOC ETV</title>
            <description>Participants with cHBV who are currently not being treated will receive matching placebo along with SOC ETV tablets orally for 24 weeks. Eligible participants may enter a separate extension study after Week 24 to start treatment on open-label ABI-H0731 for up to a year if necessary.&#xD;
SOC ETV: Participants will receive SOC ETV (0.5 mg QD) orally as per approved package insert.&#xD;
Placebo Oral Tablet: Participants will receive matching QD placebo tablets orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Abnormal Alanine Aminotransferase (ALT) at Baseline Who Have Normal ALT at Week 24 on ABI-H0731 + SOC ETV as Compared to Placebo + SOC ETV</title>
          <population>Participants in the ITT population with abnormal ALT at Baseline</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With a Decline in Viral DNA to Below Limit of Quantitation on ABI-H0731 + SOC ETV as Compared to Placebo + SOC ETV</title>
        <description>HBV DNA was measured using COBAS TaqMan Version 2.0. The LLOQ was 20 IU/mL and the LOD was 10 IU/mL. The number of participants with HBV DNA below the limit of quantitation (&lt;20 IU/mL) and target detected (≥10 IU/mL) was assessed.</description>
        <time_frame>Baseline, Weeks 2, 4, 8, 12, 16, 20, and 24</time_frame>
        <population>ITT population and had viral DNA data available</population>
        <group_list>
          <group group_id="O1">
            <title>ABI-H0731 + SOC ETV</title>
            <description>Participants with cHBV who are currently not being treated will receive ABI-H0731 along with SOC ETV tablets orally for 24 weeks. Eligible participants may enter a separate extension study after Week 24 to continue open-label ABI-H0731 for up to an additional year if necessary.&#xD;
ABI-H0731: Participants will receive 300mg QD of ABI-H0731 tablets orally.&#xD;
SOC ETV: Participants will receive SOC ETV (0.5 mg QD) orally as per approved package insert.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + SOC ETV</title>
            <description>Participants with cHBV who are currently not being treated will receive matching placebo along with SOC ETV tablets orally for 24 weeks. Eligible participants may enter a separate extension study after Week 24 to start treatment on open-label ABI-H0731 for up to a year if necessary.&#xD;
SOC ETV: Participants will receive SOC ETV (0.5 mg QD) orally as per approved package insert.&#xD;
Placebo Oral Tablet: Participants will receive matching QD placebo tablets orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Decline in Viral DNA to Below Limit of Quantitation on ABI-H0731 + SOC ETV as Compared to Placebo + SOC ETV</title>
          <description>HBV DNA was measured using COBAS TaqMan Version 2.0. The LLOQ was 20 IU/mL and the LOD was 10 IU/mL. The number of participants with HBV DNA below the limit of quantitation (&lt;20 IU/mL) and target detected (≥10 IU/mL) was assessed.</description>
          <population>ITT population and had viral DNA data available</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Time to Viral Suppression, Defined as HBV DNA &lt;20 IU/mL, on ABI-H0731 + ETV as Compared to Placebo + ETV</title>
        <description>Median time to viral suppression will be calculated and evaluated between participants on ABI-H0731 + ETV as compared to placebo + ETV.</description>
        <time_frame>Baseline, Weeks 2, 4, 8, 12, 16, 20, and 24</time_frame>
        <population>Median time to viral suppression could not be calculated because fewer than 50% of participants achieved viral suppression within 24 weeks.</population>
        <group_list>
          <group group_id="O1">
            <title>ABI-H0731 + SOC ETV</title>
            <description>Participants with cHBV who are currently not being treated will receive ABI-H0731 along with SOC ETV tablets orally for 24 weeks. Eligible participants may enter a separate extension study after Week 24 to continue open-label ABI-H0731 for up to an additional year if necessary.&#xD;
ABI-H0731: Participants will receive 300mg QD of ABI-H0731 tablets orally.&#xD;
SOC ETV: Participants will receive SOC ETV (0.5 mg QD) orally as per approved package insert.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + SOC ETV</title>
            <description>Participants with cHBV who are currently not being treated will receive matching placebo along with SOC ETV tablets orally for 24 weeks. Eligible participants may enter a separate extension study after Week 24 to start treatment on open-label ABI-H0731 for up to a year if necessary.&#xD;
SOC ETV: Participants will receive SOC ETV (0.5 mg QD) orally as per approved package insert.&#xD;
Placebo Oral Tablet: Participants will receive matching QD placebo tablets orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Time to Viral Suppression, Defined as HBV DNA &lt;20 IU/mL, on ABI-H0731 + ETV as Compared to Placebo + ETV</title>
          <description>Median time to viral suppression will be calculated and evaluated between participants on ABI-H0731 + ETV as compared to placebo + ETV.</description>
          <population>Median time to viral suppression could not be calculated because fewer than 50% of participants achieved viral suppression within 24 weeks.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Emergence of Resistant HBV Variants on ABI-H0731 + SOC ETV as Compared to Placebo + SOC ETV</title>
        <description>Emergence of a resistant HBV variant was defined as an increase of ≥1 log10 IU/mL from the nadir in HBV DNA.</description>
        <time_frame>Up to Week 36</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>ABI-H0731 + SOC ETV</title>
            <description>Participants with cHBV who are currently not being treated will receive ABI-H0731 along with SOC ETV tablets orally for 24 weeks. Eligible participants may enter a separate extension study after Week 24 to continue open-label ABI-H0731 for up to an additional year if necessary.&#xD;
ABI-H0731: Participants will receive 300mg QD of ABI-H0731 tablets orally.&#xD;
SOC ETV: Participants will receive SOC ETV (0.5 mg QD) orally as per approved package insert.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + SOC ETV</title>
            <description>Participants with cHBV who are currently not being treated will receive matching placebo along with SOC ETV tablets orally for 24 weeks. Eligible participants may enter a separate extension study after Week 24 to start treatment on open-label ABI-H0731 for up to a year if necessary.&#xD;
SOC ETV: Participants will receive SOC ETV (0.5 mg QD) orally as per approved package insert.&#xD;
Placebo Oral Tablet: Participants will receive matching QD placebo tablets orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Emergence of Resistant HBV Variants on ABI-H0731 + SOC ETV as Compared to Placebo + SOC ETV</title>
          <description>Emergence of a resistant HBV variant was defined as an increase of ≥1 log10 IU/mL from the nadir in HBV DNA.</description>
          <population>ITT population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Emergence of resistant HBV variants</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No emergence of resistant HBV variants</title>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough Levels of ABI-H0731 on ABI-H0731 + SOC ETV Therapy</title>
        <time_frame>Before dosing at Baseline (Day 1), Weeks 2, 4, 12, and 24</time_frame>
        <population>Results were analyzed and reported only for participants in the safety population who received ABI-H0731 + SOC ETV and had ABI-H0731 pharmacokinetic data assessments available.</population>
        <group_list>
          <group group_id="O1">
            <title>ABI-H0731 + SOC ETV</title>
            <description>Participants with cHBV who are currently not being treated will receive ABI-H0731 along with SOC ETV tablets orally for 24 weeks. Eligible participants may enter a separate extension study after Week 24 to continue open-label ABI-H0731 for up to an additional year if necessary.&#xD;
ABI-H0731: Participants will receive 300mg QD of ABI-H0731 tablets orally.&#xD;
SOC ETV: Participants will receive SOC ETV (0.5 mg QD) orally as per approved package insert.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough Levels of ABI-H0731 on ABI-H0731 + SOC ETV Therapy</title>
          <population>Results were analyzed and reported only for participants in the safety population who received ABI-H0731 + SOC ETV and had ABI-H0731 pharmacokinetic data assessments available.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Plasma levels for all participants were below the limit of quantitation</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1480" spread="458"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1290" spread="434"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1270" spread="413"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1470" spread="547"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough Levels of ETV on ABI-H0731 + ETV Therapy as Compared With Placebo + ETV Therapy</title>
        <time_frame>Before dosing at Baseline (Day 1), Weeks 2, 4, 12, and 24</time_frame>
        <population>Results were analyzed and reported only for participants in the safety population who had ETV pharmacokinetic data assessments available.</population>
        <group_list>
          <group group_id="O1">
            <title>ABI-H0731 + SOC ETV</title>
            <description>Participants with cHBV who are currently not being treated will receive ABI-H0731 along with SOC ETV tablets orally for 24 weeks. Eligible participants may enter a separate extension study after Week 24 to continue open-label ABI-H0731 for up to an additional year if necessary.&#xD;
ABI-H0731: Participants will receive 300mg QD of ABI-H0731 tablets orally.&#xD;
SOC ETV: Participants will receive SOC ETV (0.5 mg QD) orally as per approved package insert.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + SOC ETV</title>
            <description>Participants with cHBV who are currently not being treated will receive matching placebo along with SOC ETV tablets orally for 24 weeks. Eligible participants may enter a separate extension study after Week 24 to start treatment on open-label ABI-H0731 for up to a year if necessary.&#xD;
SOC ETV: Participants will receive SOC ETV (0.5 mg QD) orally as per approved package insert.&#xD;
Placebo Oral Tablet: Participants will receive matching QD placebo tablets orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough Levels of ETV on ABI-H0731 + ETV Therapy as Compared With Placebo + ETV Therapy</title>
          <population>Results were analyzed and reported only for participants in the safety population who had ETV pharmacokinetic data assessments available.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Day 1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00325" spread="0.0113"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.432" spread="0.126"/>
                    <measurement group_id="O2" value="0.497" spread="0.473"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.419" spread="0.119"/>
                    <measurement group_id="O2" value="0.618" spread="0.736"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.378" spread="0.149"/>
                    <measurement group_id="O2" value="0.666" spread="0.766"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.411" spread="0.143"/>
                    <measurement group_id="O2" value="0.408" spread="0.131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough to Peak Ratios of ABI-H0731 on ABI-H0731 + ETV Therapy</title>
        <time_frame>Baseline, Weeks 2, 4, 12, and 24</time_frame>
        <population>Trough to peak ratios were not calculated due to an insufficient number of optional peak exposure samples.</population>
        <group_list>
          <group group_id="O1">
            <title>ABI-H0731 + SOC ETV</title>
            <description>Participants with cHBV who are currently not being treated will receive ABI-H0731 along with SOC ETV tablets orally for 24 weeks. Eligible participants may enter a separate extension study after Week 24 to continue open-label ABI-H0731 for up to an additional year if necessary.&#xD;
ABI-H0731: Participants will receive 300mg QD of ABI-H0731 tablets orally.&#xD;
SOC ETV: Participants will receive SOC ETV (0.5 mg QD) orally as per approved package insert.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough to Peak Ratios of ABI-H0731 on ABI-H0731 + ETV Therapy</title>
          <population>Trough to peak ratios were not calculated due to an insufficient number of optional peak exposure samples.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough to Peak Ratios of ETV on ABI-H0731 + ETV Therapy as Compared With Placebo + ETV Therapy</title>
        <time_frame>Baseline, Weeks 2, 4, 12, 24, and 28</time_frame>
        <population>Trough to peak ratios were not calculated due to an insufficient number of optional peak exposure samples.</population>
        <group_list>
          <group group_id="O1">
            <title>ABI-H0731 + SOC ETV</title>
            <description>Participants with cHBV who are currently not being treated will receive ABI-H0731 along with SOC ETV tablets orally for 24 weeks. Eligible participants may enter a separate extension study after Week 24 to continue open-label ABI-H0731 for up to an additional year if necessary.&#xD;
ABI-H0731: Participants will receive 300mg QD of ABI-H0731 tablets orally.&#xD;
SOC ETV: Participants will receive SOC ETV (0.5 mg QD) orally as per approved package insert.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + SOC ETV</title>
            <description>Participants with cHBV who are currently not being treated will receive matching placebo along with SOC ETV tablets orally for 24 weeks. Eligible participants may enter a separate extension study after Week 24 to start treatment on open-label ABI-H0731 for up to a year if necessary.&#xD;
SOC ETV: Participants will receive SOC ETV (0.5 mg QD) orally as per approved package insert.&#xD;
Placebo Oral Tablet: Participants will receive matching QD placebo tablets orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough to Peak Ratios of ETV on ABI-H0731 + ETV Therapy as Compared With Placebo + ETV Therapy</title>
          <population>Trough to peak ratios were not calculated due to an insufficient number of optional peak exposure samples.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to Week 36</time_frame>
      <desc>Safety population</desc>
      <group_list>
        <group group_id="E1">
          <title>ABI-H0731 + SOC ETV</title>
          <description>Participants with cHBV who are currently not being treated will receive ABI-H0731 along with SOC ETV tablets orally for 24 weeks. Eligible participants may enter a separate extension study after Week 24 to continue open-label ABI-H0731 for up to an additional year if necessary.&#xD;
ABI-H0731: Participants will receive 300mg QD of ABI-H0731 tablets orally.&#xD;
SOC ETV: Participants will receive SOC ETV (0.5 mg QD) orally as per approved package insert.</description>
        </group>
        <group group_id="E2">
          <title>Placebo + SOC ETV</title>
          <description>Participants with cHBV who are currently not being treated will receive matching placebo along with SOC ETV tablets orally for 24 weeks. Eligible participants may enter a separate extension study after Week 24 to start treatment on open-label ABI-H0731 for up to a year if necessary.&#xD;
SOC ETV: Participants will receive SOC ETV (0.5 mg QD) orally as per approved package insert.&#xD;
Placebo Oral Tablet: Participants will receive matching QD placebo tablets orally.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 21.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Electrocardiogram T wave abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Stress</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Skin irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Assembly Biosciences agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Assembly Biosciences supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Linda Baher, Sr. Director, Clinical Operations</name_or_title>
      <organization>Assembly Biosciences</organization>
      <phone>415-521-3808</phone>
      <email>clinicaltrials@assemblybio.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

